Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-21-037786
Filing Date
2021-06-03
Accepted
2021-06-03 17:27:36
Documents
1
Period of Report
2021-06-01

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4588
  Complete submission text file 0001209191-21-037786.txt   6028
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address
GORDON CARL L (Reporting) CIK: 0001282930 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39264 | Film No.: 21993688

Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Issuer) CIK: 0001664710 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations